Schedule 13G ownership disclosure
ASCENDIS PHARMA A/S
ADR · CUSIP: 04351P101
Event date: 2025-06-30
- Filing-level shares
- 3,583,546
- Percent of class
- 6.4%
- T. Rowe Price Investment Management, Inc.
Shares: 3,583,546 · Class: 6.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001897612-25-000368
- Form type
- SCHEDULE 13G/A
- Filer
- Ascendis Pharma A/S
- CIK
- CIK 1612042
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership